Jennison Associates LLC Acquires Shares of 1,533,371 Teva Pharmaceutical Industries Ltd. $TEVA

Jennison Associates LLC purchased a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 1,533,371 shares of the company’s stock, valued at approximately $47,857,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in TEVA. Wellington Management Group LLP boosted its position in Teva Pharmaceutical Industries by 39,228.4% during the third quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock worth $139,296,000 after acquiring an additional 6,878,304 shares during the last quarter. Farallon Capital Management LLC acquired a new position in Teva Pharmaceutical Industries in the 3rd quarter valued at about $100,939,000. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in Teva Pharmaceutical Industries by 14.8% in the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company’s stock valued at $1,167,323,000 after purchasing an additional 4,820,000 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Teva Pharmaceutical Industries by 12.9% in the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock valued at $761,455,000 after buying an additional 4,306,363 shares during the period. Finally, Polar Capital Holdings Plc purchased a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $80,983,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $35.03 on Friday. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $14.99 and a fifty-two week high of $37.35. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. The company has a 50 day moving average price of $31.15 and a 200 day moving average price of $29.33. The stock has a market capitalization of $40.28 billion, a P/E ratio of 26.34, a PEG ratio of 3.12 and a beta of 0.76.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a return on equity of 44.86% and a net margin of 9.01%.The company had revenue of $3.98 billion for the quarter. Equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.6 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, April 20th. Jefferies Financial Group increased their price target on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Barclays raised their price objective on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. Finally, Bank of America boosted their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 9th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $41.56.

Key Stories Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q1 results beat and fundamentals: Teva reported Q1 revenue of ~$4.0B and EPS that topped estimates, driven by branded drugs (Austedo, Ajovy, Uzedy). Management reiterated FY guidance in line with consensus, supporting the near‑term re‑rating thesis. Reuters: Teva beats Q1 profit estimates
• Positive Sentiment: Acquisition expands pipeline: Teva agreed to acquire Emalex (deal reports cite up to ~$900M) to add ecopipam, an NDA‑ready first‑in‑class pediatric Tourette therapy — a strategic, late‑stage asset that supports longer‑term growth. GlobeNewswire: Teva to acquire Emalex
• Positive Sentiment: Multiple analyst upgrades and higher targets: Truist raised its price target to $45 (buy), UBS to $42 (buy), JPMorgan to $40 (overweight), and Piper Sandler reaffirmed overweight at $42 — implying double‑digit upside from current levels and likely supporting buying interest. Benzinga: analyst actions
• Positive Sentiment: Institutional / financing interest: Reports of a $400M Blackstone commitment/financing and unusually large call option activity signal bullish institutional positioning. Fool: Blackstone bet
• Neutral Sentiment: Sustainability milestone: Teva said it met all sustainability‑linked bond targets (~$7.5B of bonds), which reduces ESG-related refinancing risk and links some financial outcomes to ESG KPIs. GlobeNewswire: Healthy Future Report
• Neutral Sentiment: Market research mention: Teva appears in industry reports as a leading player in oral solid dosage CMOs, which is positive for strategic positioning but not an immediate stock catalyst. ResearchAndMarkets / Yahoo
• Negative Sentiment: Generics weakness and near‑term headwinds: Management noted weaker generics revenue (including lenalidomide capsule impacts), a factor that trims margin visibility and may limit near‑term upside despite branded growth. GlobeNewswire: Q1 results

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Brian Savage sold 1,127 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $35,692.09. Following the completion of the transaction, the insider directly owned 10,914 shares of the company’s stock, valued at $345,646.38. The trade was a 9.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Richard Daniell sold 17,295 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $547,732.65. Following the completion of the transaction, the executive vice president directly owned 85,755 shares of the company’s stock, valued at approximately $2,715,860.85. This represents a 16.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 920,901 shares of company stock worth $30,056,789. 0.54% of the stock is owned by corporate insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.